Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate

globenewswire.com
TMO BIO QGEN

Viral Vector Manufacturing - Global Strategic Business Report: Capitalize on 18.3% CAGR to US$2.6 Billion by 2030 as Bayer, Janssen, Aldevron, GenScript, and Cytiva Reshape Gene Therapy

globenewswire.com
JNJ

Single-Cell Analysis - Global Strategic Business Report 2026: Capitalize on 20.4% CAGR as Illumina, Thermo Fisher Scientific, Bio-Rad and Agilent Battle for Shares in the $26.1 Billion Market by 2032

globenewswire.com
ILMN TMO BIO

Global High-Resolution Melting Analysis Market Outlook 2026-2032 | Which Companies Are Shaping the Competitive Landscape?

globenewswire.com
BIO ILMN TMO

Human Identification - Global Strategic Business Report 2026: Capitalize on 10.1% CAGR to $1.9 Billion by 2032 | Thermo Fisher, Illumina, Qiagen and Bio-Rad Vie for Shares

globenewswire.com
TMO ILMN QGEN BIO

Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid Tariff Shifts

globenewswire.com
ABT A BIO ILMN

Epigenetics - Global Strategic Business Report: Capitalize on an 18.2% CAGR to Secure the $5.5 Billion 2030 Market as Illumina, Thermo Fisher Scientific, Qiagen, and Bio-Rad Disrupt Precision Medicine

globenewswire.com
ILMN TMO QGEN BIO PACB

Arrive AI Announces Strategic Investment in Ottonomy to Accelerate Autonomous Delivery Network Expansion

accessnewswire.com
ARAI

Trust3 AI Ships the First Context-Driven AI Agent Kill Switch

businesswire.com
MSFT NVDA SNOW

Gene Therapy - Global Strategic Business Report: Capitalize on 23% CAGR as the Market Hits US$6 Billion by 2030; Benchmark Amgen, Alnylam, BioMarin, Biogen and bluebird bio

globenewswire.com
AMGN ALNY BMRN BIIB
View all news →